Predicting long-term sustained disability progression in multiple sclerosis
ECTRIMS Online Library. Sharmin S. 09/13/19; 279563; 304
Sifat Sharmin
Sifat Sharmin
Contributions
Abstract

Abstract: 304

Type: Scientific Session

Abstract Category: Therapy - Long-term treatment monitoring

S. Sharmin1, C. Malpas1, D. Horakova2,3, E.K. Havrdova2,3, G. Izquierdo4, S. Eichau4, M. Trojano5, A. Prat6, M. Girard6, P. Duquette6, M. Onofrj7, A. Lugaresi8,9, F. Grand'Maison10, P. Grammond11, P. Sola12, D. Ferraro12, M. Terzi13, R. Hupperts14, R. Alroughani15, C. Boz16, V. Shaygannejad17, V. Van Pesch18,19, E. Cartechini20, L. Kappos21,22, J. Lechner-Scott23,24, R. Bergamaschi25, R. Turkoglu26, C. Solaro27,28, C. Ramo-Tello29, G. Iuliano30, F. Granella31,32, B. Van Wijmeersch33, D. Spitaleri34, R.F. Bolaños35, M. Slee36, P. McCombe37,38, J. Prevost39, R. Ampapa40, S. Ozakbas41, J.L. Sanchez-Menoyo42, A. Soysal43, S. Vucic44, T. Petersen45, F. Verheul46, E. Butler47, S. Hodgkinson48, Y. Sidhom49, R. Gouider49, H. Butzkueven50,51,52, T. Kalincik1, on behalf of the MSBase Registry

1CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia, 2Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, 3General University Hospital, Prague, Czech Republic, 4Hospital Universitario Virgen Macarena, Sevilla, Spain, 5Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy, 6Hopital Notre Dame, Montreal, Canada; CHUM and Universite de Montreal, Montreal, QC, Canada, 7Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, 8IRCCS Istituto delle Scienze Neurologiche di Bologna, 9Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy, 10Neuro Rive-Sud, Quebec, 11CISSS Chaudière-Appalache, Levis, QC, Canada, 12Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy, 13Medical Faculty, 19 Mayis University, Samsun, Turkey, 14Zuyderland Ziekenhuis, Sittard, The Netherlands, 15Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait, 16KTU Medical Faculty Farabi Hospital, Trabzon, Turkey, 17Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran, 18Cliniques Universitaires Saint-Luc, 19Université Catholique de Louvain, Brussels, Belgium, 20UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy, 21Neurologic Clinic and Policlinic, Departments of Medicine and Clinical Research, University Hospital, 22University of Basel, Basel, Switzerland, 23School of Medicine and Public Health, University of Newcastle, 24Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia, 25IRCCS Mondino Foundation, Pavia, Italy, 26Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey, 27Department of Neurology, ASL3 Genovese, 28Department of Rehabilitaiton, ML Novarese Hospital Moncrivello, Genova, Italy, 29Hospital Germans Trias i Pujol, Badalona, Spain, 30Ospedali Riuniti di Salerno, Salerno, 31Department of Medicine and Surgery, University of Parma, 32Department of Emergency and General Medicine, Parma University Hospital, Parma, Italy, 33Rehabilitation & MS Center Overpelt and Hasselt University, Hasselt, Belgium, 34Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy, 35Hospital Universitario Virgen de Valme, Seville, Spain, 36Flinders University, Adelaide, SA, 37University of Queensland, 38Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia, 39CSSS Saint-Jérôme, Saint-Jérôme, QC, Canada, 40Nemocnice Jihlava, Jihlava, Czech Republic, 41Dokuz Eylul University, Konak/Izmir, Turkey, 42Hospital de Galdakao-Usansolo, Galdakao, Spain, 43Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey, 44Westmead Hospital, Sydney, NSW, Australia, 45Kommunehospitalet, Arhus C, Denmark, 46Groene Hart Ziekenhuis, Gouda, The Netherlands, 47Monash Medical Centre, Melbourne, VIC, 48Liverpool Hospital, Sydney, NSW, Australia, 49Department of Neurology, Razi Hospital, Manouba, Tunisia, 50Central Clinical School, Monash University, 51Department of Neurology, The Alfred Hospital, 52Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia

Introduction: Prevention of disability over the long-term is currently the main treatment goal in multiple sclerosis (MS). Randomized clinical trials evaluate short-term treatment effect on disability in the form of 3-6-month confirmed disability progression. Using global MSBase registry, this study establishes 6-month confirmed disability progression events as indicators of long-term disability worsening suitable for use in randomized clinical trials.
Methods: A Cox proportional hazards model in the development cohort identified associations between demographic and clinical variables at the time of disability progression and the probability of an event not being sustained in the future. The coefficients from this model were used to calculate a sustained progression score. Its association with the risk that an event will be sustained over timewas evaluated with a Cox model in the validation cohort.
Results: 11,435 confirmed progression events identified in 6,902 patients constituted the development cohort. Patient characteristics at the time of progression associated with lower probability of subsequent improvement were age (hazard ratio (HR)=0.98), primary progressive (HR=0.37) and progressive-relapsing (HR=0.36) MS, expanded disability status scale score >=6 (HR=0.71) and its change from baseline (HR=0.67), number of affected functional system scores (HR=0.92) and pyramidal(HR=0.79) functional system score (p< 0.05). The strength of the association with pyramidal score decreased with time(HR=1.01). Occurrence of a relapse within previous month (HR=1.46) and worsening in sensory functional system score (HR=1.17) were associated with higher probability of improvement after progression. The associations were confirmed by two sensitivity analyses. The sustained progression score, ranged 0.39-4.79 in the validation cohort with 1,271 progression events, estimated a 53% lower chance of improvement with each unit increase in the score (HR=0.47, 95% confidence interval 0.35-0.63). The proportions of progression events sustained at 5 years stratified by the score were 1: 68%, 2: 79%, 3: 94%, 4: 100%.
Conclusion: Estimate of the probability of disability progression events being sustained over the long term provides important information complementary to the incidence of disability progression events. This information will enable future trials to establish the effect of therapy not only on the short-term but also on long-term disability accrual.
Disclosure: Sifat Sharmin: nothing to disclose
Charles Malpas: nothing to disclose
Dana Horakova: received speaker honoraria and consulting fees from Biogen, Merck, Teva, Roche, Sanofi Genzyme, and Novartis, as well as support for research activities from Biogen and Czech Minsitry of Education [project Progres Q27/LF1].
Eva Kubala Havrdova: received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education [project Progres Q27/LF1].
Guillermo Izquierdo: received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva
Sara Eichau: nothing to disclose
Maria Trojano: received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis
Alexandre Prat: nothing to disclose
Marc Girard: received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD .? He has also received a research grant from Canadian Institutes of Health Research.
Pierre Duquette: served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme
Marco Onofrj: nothing to disclose
Alessandra Lugaresi: served as a Bayer, Biogen, Merck, Novartis, Roche, Sanofi/ Genzyme and Teva Advisory Board Member. She received congress and travel/accommodation expense compensations and speaker honoraria from Bayer, Biogen, Merck, Novartis, Sanofi/Genzyme, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis
Francois Grand´Maison: received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals
Pierre Grammond: is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis
Patrizia Sola: served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva
Diana Ferraro: received travel grants and/or speaker honoraria from Merck, TEVA,?Novartis, Biogen and Sanofi-Genzyme
Murat Terzi: received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis
Raymond Hupperts: received honoraria as consultant on scientific advisory boards from Merck, Biogen, Genzyme-Sanofi and Teva, research funding from Merck and Biogen, and speaker honoraria from Sanofi-Genzyme and Novartis
Raed Alroughani: received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme
Cavit Boz: received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.
Vahid Shaygannejad: nothing to disclose
Vincent Van Pesch: received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering
Elisabetta Cartechini: nothing to disclose
Ludwig Kappos: received research support from Acorda, Actelion, Allozyne, BaroFold, Bayer HealthCare, Bayer Schering, Bayhill Therapeutics, Biogen, Elan, European Union, Genmab, Gianni Rubatto Foundation, GlaxoSmithKline, Glenmark, MediciNova, Merck, Novartis, Novartis Research Foundation, Roche, Roche Research Foundation, Sanofi-Aventis, Santhera, Swiss MS Society, Swiss National Research Foundation, Teva Neuroscience, UCB, and Wyeth
Jeannette Lechner-Scott: accepted travel compensation from Novartis, Biogen and Merck. Her institution receives the honoraria for talks and advisory board commitment from Bayer Health Care, Biogen, Genzyme Sanofi, Merck, Novartis and Teva, has been involved in clinical trials with Biogen, Novartis and Teva
Roberto Bergamaschi: received speaker honoraria from Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva; research grants from Bayer Schering, Biogen, Merck, Novartis, Sanofi-Aventis, Teva; congress and travel/accommodation expense compensations by Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva
Recai Turkoglu: nothing to disclose
Claudio Solaro: served on scientific advisory boards for Merck, Genzyme, Almirall, and Biogen; received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva
Cristina Ramo-Tello: received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall
Gerardo Iuliano: had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck, Novartis, Sanofi Aventis, and Teva
Franco Granella: received an institutional research grant from Biogen and Sanofi Genzyme, served on scientific advisory boards for Biogen, Novartis, Merck, Sanofi Genzyme and Roche, received funding for travel and speaker honoraria from Biogen, Merck, and Sanofi-Aventis
Bart Van Wijmeersch: received research and rravel grants, honoraria for MS-Expert advisor and Speaker fees from Bayer-Schering, Biogen, Sanofi Genzyme, Merck, Novartis, Roche and Teva
Daniele Spitaleri: received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva and Merck
Ricardo Fernandez Bolanos: received speaking honoraria from Biogen, Novartis, Merck and Teva
Mark Slee: has participated in, but not received honoraria for, advisory board activity for Biogen, Merck, Bayer Schering, Sanofi Aventis and Novartis
Pamela McCombe: nothing to disclose
Julie Prevost: accepted travel compensation from Novartis, Biogen, Genzyme, Teva, and speaking honoraria from Biogen, Novartis, Genzyme and Teva
Radek Ampapa: received conference travel support from Novartis, Teva, Biogen, Bayer and Merck and has participated in a clinical trials by Biogen, Novartis, Teva and Actelion.
Serkan Ozakbas: nothing to disclose
Jose Luis Sanchez-Menoyo: accepted travel compensation from Novartis and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in a clinical trial by Biogen
Aysun Soysal: nothing to disclose
Steve Vucic: nothing to disclose
Thor Petersen: received funding or speaker honoraria from Biogen, Merck, Novartis, Bayer Schering, Sanofi-Aventis, Roche, and Genzyme
Freek Verheul: is an advisory board member for Teva Biogen Merck and Novartis
Ernest Butler: nothing to disclose
Suzanne Hodgkinson: received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering
Youssef Sidhom: nothing to disclose
Riadh Gouider: nothing to disclose
Helmut Butzkueven: served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen and Novartis, and has received research support from Merck, Novartis and Biogen
Tomas Kalincik: served on scientific advisory boards for Roche, Sanofi-Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen

Abstract: 304

Type: Scientific Session

Abstract Category: Therapy - Long-term treatment monitoring

S. Sharmin1, C. Malpas1, D. Horakova2,3, E.K. Havrdova2,3, G. Izquierdo4, S. Eichau4, M. Trojano5, A. Prat6, M. Girard6, P. Duquette6, M. Onofrj7, A. Lugaresi8,9, F. Grand'Maison10, P. Grammond11, P. Sola12, D. Ferraro12, M. Terzi13, R. Hupperts14, R. Alroughani15, C. Boz16, V. Shaygannejad17, V. Van Pesch18,19, E. Cartechini20, L. Kappos21,22, J. Lechner-Scott23,24, R. Bergamaschi25, R. Turkoglu26, C. Solaro27,28, C. Ramo-Tello29, G. Iuliano30, F. Granella31,32, B. Van Wijmeersch33, D. Spitaleri34, R.F. Bolaños35, M. Slee36, P. McCombe37,38, J. Prevost39, R. Ampapa40, S. Ozakbas41, J.L. Sanchez-Menoyo42, A. Soysal43, S. Vucic44, T. Petersen45, F. Verheul46, E. Butler47, S. Hodgkinson48, Y. Sidhom49, R. Gouider49, H. Butzkueven50,51,52, T. Kalincik1, on behalf of the MSBase Registry

1CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia, 2Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, 3General University Hospital, Prague, Czech Republic, 4Hospital Universitario Virgen Macarena, Sevilla, Spain, 5Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy, 6Hopital Notre Dame, Montreal, Canada; CHUM and Universite de Montreal, Montreal, QC, Canada, 7Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, 8IRCCS Istituto delle Scienze Neurologiche di Bologna, 9Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy, 10Neuro Rive-Sud, Quebec, 11CISSS Chaudière-Appalache, Levis, QC, Canada, 12Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy, 13Medical Faculty, 19 Mayis University, Samsun, Turkey, 14Zuyderland Ziekenhuis, Sittard, The Netherlands, 15Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait, 16KTU Medical Faculty Farabi Hospital, Trabzon, Turkey, 17Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran, 18Cliniques Universitaires Saint-Luc, 19Université Catholique de Louvain, Brussels, Belgium, 20UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy, 21Neurologic Clinic and Policlinic, Departments of Medicine and Clinical Research, University Hospital, 22University of Basel, Basel, Switzerland, 23School of Medicine and Public Health, University of Newcastle, 24Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia, 25IRCCS Mondino Foundation, Pavia, Italy, 26Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey, 27Department of Neurology, ASL3 Genovese, 28Department of Rehabilitaiton, ML Novarese Hospital Moncrivello, Genova, Italy, 29Hospital Germans Trias i Pujol, Badalona, Spain, 30Ospedali Riuniti di Salerno, Salerno, 31Department of Medicine and Surgery, University of Parma, 32Department of Emergency and General Medicine, Parma University Hospital, Parma, Italy, 33Rehabilitation & MS Center Overpelt and Hasselt University, Hasselt, Belgium, 34Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy, 35Hospital Universitario Virgen de Valme, Seville, Spain, 36Flinders University, Adelaide, SA, 37University of Queensland, 38Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia, 39CSSS Saint-Jérôme, Saint-Jérôme, QC, Canada, 40Nemocnice Jihlava, Jihlava, Czech Republic, 41Dokuz Eylul University, Konak/Izmir, Turkey, 42Hospital de Galdakao-Usansolo, Galdakao, Spain, 43Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey, 44Westmead Hospital, Sydney, NSW, Australia, 45Kommunehospitalet, Arhus C, Denmark, 46Groene Hart Ziekenhuis, Gouda, The Netherlands, 47Monash Medical Centre, Melbourne, VIC, 48Liverpool Hospital, Sydney, NSW, Australia, 49Department of Neurology, Razi Hospital, Manouba, Tunisia, 50Central Clinical School, Monash University, 51Department of Neurology, The Alfred Hospital, 52Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia

Introduction: Prevention of disability over the long-term is currently the main treatment goal in multiple sclerosis (MS). Randomized clinical trials evaluate short-term treatment effect on disability in the form of 3-6-month confirmed disability progression. Using global MSBase registry, this study establishes 6-month confirmed disability progression events as indicators of long-term disability worsening suitable for use in randomized clinical trials.
Methods: A Cox proportional hazards model in the development cohort identified associations between demographic and clinical variables at the time of disability progression and the probability of an event not being sustained in the future. The coefficients from this model were used to calculate a sustained progression score. Its association with the risk that an event will be sustained over timewas evaluated with a Cox model in the validation cohort.
Results: 11,435 confirmed progression events identified in 6,902 patients constituted the development cohort. Patient characteristics at the time of progression associated with lower probability of subsequent improvement were age (hazard ratio (HR)=0.98), primary progressive (HR=0.37) and progressive-relapsing (HR=0.36) MS, expanded disability status scale score >=6 (HR=0.71) and its change from baseline (HR=0.67), number of affected functional system scores (HR=0.92) and pyramidal(HR=0.79) functional system score (p< 0.05). The strength of the association with pyramidal score decreased with time(HR=1.01). Occurrence of a relapse within previous month (HR=1.46) and worsening in sensory functional system score (HR=1.17) were associated with higher probability of improvement after progression. The associations were confirmed by two sensitivity analyses. The sustained progression score, ranged 0.39-4.79 in the validation cohort with 1,271 progression events, estimated a 53% lower chance of improvement with each unit increase in the score (HR=0.47, 95% confidence interval 0.35-0.63). The proportions of progression events sustained at 5 years stratified by the score were 1: 68%, 2: 79%, 3: 94%, 4: 100%.
Conclusion: Estimate of the probability of disability progression events being sustained over the long term provides important information complementary to the incidence of disability progression events. This information will enable future trials to establish the effect of therapy not only on the short-term but also on long-term disability accrual.
Disclosure: Sifat Sharmin: nothing to disclose
Charles Malpas: nothing to disclose
Dana Horakova: received speaker honoraria and consulting fees from Biogen, Merck, Teva, Roche, Sanofi Genzyme, and Novartis, as well as support for research activities from Biogen and Czech Minsitry of Education [project Progres Q27/LF1].
Eva Kubala Havrdova: received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education [project Progres Q27/LF1].
Guillermo Izquierdo: received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva
Sara Eichau: nothing to disclose
Maria Trojano: received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis
Alexandre Prat: nothing to disclose
Marc Girard: received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD .? He has also received a research grant from Canadian Institutes of Health Research.
Pierre Duquette: served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme
Marco Onofrj: nothing to disclose
Alessandra Lugaresi: served as a Bayer, Biogen, Merck, Novartis, Roche, Sanofi/ Genzyme and Teva Advisory Board Member. She received congress and travel/accommodation expense compensations and speaker honoraria from Bayer, Biogen, Merck, Novartis, Sanofi/Genzyme, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis
Francois Grand´Maison: received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals
Pierre Grammond: is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis
Patrizia Sola: served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva
Diana Ferraro: received travel grants and/or speaker honoraria from Merck, TEVA,?Novartis, Biogen and Sanofi-Genzyme
Murat Terzi: received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis
Raymond Hupperts: received honoraria as consultant on scientific advisory boards from Merck, Biogen, Genzyme-Sanofi and Teva, research funding from Merck and Biogen, and speaker honoraria from Sanofi-Genzyme and Novartis
Raed Alroughani: received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme
Cavit Boz: received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.
Vahid Shaygannejad: nothing to disclose
Vincent Van Pesch: received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering
Elisabetta Cartechini: nothing to disclose
Ludwig Kappos: received research support from Acorda, Actelion, Allozyne, BaroFold, Bayer HealthCare, Bayer Schering, Bayhill Therapeutics, Biogen, Elan, European Union, Genmab, Gianni Rubatto Foundation, GlaxoSmithKline, Glenmark, MediciNova, Merck, Novartis, Novartis Research Foundation, Roche, Roche Research Foundation, Sanofi-Aventis, Santhera, Swiss MS Society, Swiss National Research Foundation, Teva Neuroscience, UCB, and Wyeth
Jeannette Lechner-Scott: accepted travel compensation from Novartis, Biogen and Merck. Her institution receives the honoraria for talks and advisory board commitment from Bayer Health Care, Biogen, Genzyme Sanofi, Merck, Novartis and Teva, has been involved in clinical trials with Biogen, Novartis and Teva
Roberto Bergamaschi: received speaker honoraria from Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva; research grants from Bayer Schering, Biogen, Merck, Novartis, Sanofi-Aventis, Teva; congress and travel/accommodation expense compensations by Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva
Recai Turkoglu: nothing to disclose
Claudio Solaro: served on scientific advisory boards for Merck, Genzyme, Almirall, and Biogen; received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva
Cristina Ramo-Tello: received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall
Gerardo Iuliano: had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck, Novartis, Sanofi Aventis, and Teva
Franco Granella: received an institutional research grant from Biogen and Sanofi Genzyme, served on scientific advisory boards for Biogen, Novartis, Merck, Sanofi Genzyme and Roche, received funding for travel and speaker honoraria from Biogen, Merck, and Sanofi-Aventis
Bart Van Wijmeersch: received research and rravel grants, honoraria for MS-Expert advisor and Speaker fees from Bayer-Schering, Biogen, Sanofi Genzyme, Merck, Novartis, Roche and Teva
Daniele Spitaleri: received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva and Merck
Ricardo Fernandez Bolanos: received speaking honoraria from Biogen, Novartis, Merck and Teva
Mark Slee: has participated in, but not received honoraria for, advisory board activity for Biogen, Merck, Bayer Schering, Sanofi Aventis and Novartis
Pamela McCombe: nothing to disclose
Julie Prevost: accepted travel compensation from Novartis, Biogen, Genzyme, Teva, and speaking honoraria from Biogen, Novartis, Genzyme and Teva
Radek Ampapa: received conference travel support from Novartis, Teva, Biogen, Bayer and Merck and has participated in a clinical trials by Biogen, Novartis, Teva and Actelion.
Serkan Ozakbas: nothing to disclose
Jose Luis Sanchez-Menoyo: accepted travel compensation from Novartis and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in a clinical trial by Biogen
Aysun Soysal: nothing to disclose
Steve Vucic: nothing to disclose
Thor Petersen: received funding or speaker honoraria from Biogen, Merck, Novartis, Bayer Schering, Sanofi-Aventis, Roche, and Genzyme
Freek Verheul: is an advisory board member for Teva Biogen Merck and Novartis
Ernest Butler: nothing to disclose
Suzanne Hodgkinson: received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering
Youssef Sidhom: nothing to disclose
Riadh Gouider: nothing to disclose
Helmut Butzkueven: served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen and Novartis, and has received research support from Merck, Novartis and Biogen
Tomas Kalincik: served on scientific advisory boards for Roche, Sanofi-Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies